Details

Autor(en) / Beteiligte

• Díez‐Campelo, María
• Lorenzo, Jose I.
• Itzykson, Raphael
• Rojas, Silvia M.
• Berthon, Céline
• Luño, Elisa
• Beyne‐Rauzy, Odile
• Perez‐Oteyza, Jaime
• Vey, Norbert
• Bargay, Joan
• Park, Sophie
• Cedena, Teresa
• Bordessoule, Dominique
• Muñoz, Juan A.
• Gyan, Emmanuel
• Such, Esperanza
• Visanica, Sorin
• López‐Cadenas, Félix
• Botton, Stéphane
• Hernández‐Rivas, Jesús M.
• Ame, Shanti
• Stamatoullas, Aspasia
• Delaunay, Jacques
• Salanoubat, Celia
• Isnard, Françoise
• Guieze, Romain
• Pérez Guallar, Joan
• Badiella, Llorenc
• Sanz, Guillermo
• Cañizo, Consuelo
• Fenaux, Pierre

Titel

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

Ist Teil von

• British journal of haematology, 2018-05, Vol.181 (3), p.350-359

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2018

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Summary Treatment with azacitidine (AZA) has been suggested to be of benefit for higher‐risk myelodysplastic syndrome (HR‐MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR‐MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time‐varying variable in multivariable analysis. A Cox Regression model with time‐interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non‐CK) and International Prognostic Scoring System risk (high versus intermediate‐2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P < 0·001 at 1 year, 0·7 P = 0·019 at 2 years; 0·73 P = 0·029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non‐CK patients, P < 0·05 for all). AZA also significantly improved progression‐free survival (P < 0·01). This study confirms a time‐dependent benefit of AZA on outcome in patients with HR‐MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK.